Gastric Cancer, Version 2.2025

Jaffer A. Ajani; Thomas A. D’Amico; David J. Bentrem; Carlos U. Corvera; Prajnan Das; Peter C. Enzinger; Thomas Enzler; Hans Gerdes; Michael K. Gibson; Patrick Grierson; Garima Gupta; Wayne L. Hofstetter; David H. Ilson; Shadia Jalal; Sunnie Kim; Lawrence R. Kleinberg; Samuel Klempner; Jill Lacy; Byrne Lee; Frank Licciardi; Shane Lloyd; Quan P. Ly; Karen Matsukuma; Michael McNamara; Ryan P. Merkow; Aaron M. Miller; Sarbajit Mukherjee; Mary F. Mulcahy; Kyle A. Perry; Jose M. Pimiento; Deepti M. Reddi; Scott Reznik; Robert E. Roses; Vivian E. Strong; Stacey Su; Nataliya Uboha; Zev A. Wainberg; Christopher G. Willett; Yanghee Woo; Harry H. Yoon; Nicole R. McMillian; Mary Elizabeth Stein

doi:10.6004/jnccn.2025.0022

Gastric Cancer, Version 2.2025

Jaffer A. Ajani
, Thomas A. D’Amico
, David J. Bentrem
, Carlos U. Corvera
, Prajnan Das
, Peter C. Enzinger
, Thomas Enzler
, Hans Gerdes
, Michael K. Gibson
, Patrick Grierson
, Garima Gupta
, Wayne L. Hofstetter
, David H. Ilson
, Shadia Jalal
, Sunnie Kim
, Lawrence R. Kleinberg
, Samuel Klempner
, Jill Lacy
, Byrne Lee
, Frank Licciardi

Shane Lloyd, Quan P. Ly, Karen Matsukuma, Michael McNamara, Ryan P. Merkow, Aaron M. Miller, Sarbajit Mukherjee, Mary F. Mulcahy, Kyle A. Perry, Jose M. Pimiento, Deepti M. Reddi, Scott Reznik, Robert E. Roses, Vivian E. Strong, Stacey Su, Nataliya Uboha, Zev A. Wainberg, Christopher G. Willett, Yanghee Woo, Harry H. Yoon, Nicole R. McMillian, Mary Elizabeth Stein

Research output: Contribution to journal › Article › peer-review

64 Scopus citations

Abstract

Gastric cancer is the fifth leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improve survival, and enhance the quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing has had a significant impact on clinical practice and patient care. Targeted therapies have demonstrated encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. This selection from the NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer highlights recommendations for biomarker testing and discusses updates for the treatment of advanced disease, including peritoneal carcinoma as only disease and unresectable locally advanced, recurrent, or metastatic disease.

Original language	English
Pages (from-to)	169-191
Number of pages	23
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	23
Issue number	5
DOIs	https://doi.org/10.6004/jnccn.2025.0022
State	Published - May 2025

Access to Document

10.6004/jnccn.2025.0022

Cite this

Ajani, J. A., D’Amico, T. A., Bentrem, D. J., Corvera, C. U., Das, P., Enzinger, P. C., Enzler, T., Gerdes, H., Gibson, M. K., Grierson, P., Gupta, G., Hofstetter, W. L., Ilson, D. H., Jalal, S., Kim, S., Kleinberg, L. R., Klempner, S., Lacy, J., Lee, B., ... Stein, M. E. (2025). Gastric Cancer, Version 2.2025. JNCCN Journal of the National Comprehensive Cancer Network, 23(5), 169-191. https://doi.org/10.6004/jnccn.2025.0022

@article{dc488f7748a44575bb322624e37e7c1d,

title = "Gastric Cancer, Version 2.2025",

abstract = "Gastric cancer is the fifth leading cause of cancer-related deaths worldwide. Over 95\% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improve survival, and enhance the quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing has had a significant impact on clinical practice and patient care. Targeted therapies have demonstrated encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. This selection from the NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer highlights recommendations for biomarker testing and discusses updates for the treatment of advanced disease, including peritoneal carcinoma as only disease and unresectable locally advanced, recurrent, or metastatic disease.",

author = "Ajani, \{Jaffer A.\} and D{\textquoteright}Amico, \{Thomas A.\} and Bentrem, \{David J.\} and Corvera, \{Carlos U.\} and Prajnan Das and Enzinger, \{Peter C.\} and Thomas Enzler and Hans Gerdes and Gibson, \{Michael K.\} and Patrick Grierson and Garima Gupta and Hofstetter, \{Wayne L.\} and Ilson, \{David H.\} and Shadia Jalal and Sunnie Kim and Kleinberg, \{Lawrence R.\} and Samuel Klempner and Jill Lacy and Byrne Lee and Frank Licciardi and Shane Lloyd and Ly, \{Quan P.\} and Karen Matsukuma and Michael McNamara and Merkow, \{Ryan P.\} and Miller, \{Aaron M.\} and Sarbajit Mukherjee and Mulcahy, \{Mary F.\} and Perry, \{Kyle A.\} and Pimiento, \{Jose M.\} and Reddi, \{Deepti M.\} and Scott Reznik and Roses, \{Robert E.\} and Strong, \{Vivian E.\} and Stacey Su and Nataliya Uboha and Wainberg, \{Zev A.\} and Willett, \{Christopher G.\} and Yanghee Woo and Yoon, \{Harry H.\} and McMillian, \{Nicole R.\} and Stein, \{Mary Elizabeth\}",

year = "2025",

month = may,

doi = "10.6004/jnccn.2025.0022",

language = "English",

volume = "23",

pages = "169--191",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "5",

}

Ajani, JA, D’Amico, TA, Bentrem, DJ, Corvera, CU, Das, P, Enzinger, PC, Enzler, T, Gerdes, H, Gibson, MK, Grierson, P, Gupta, G, Hofstetter, WL, Ilson, DH, Jalal, S, Kim, S, Kleinberg, LR, Klempner, S, Lacy, J, Lee, B, Licciardi, F, Lloyd, S, Ly, QP, Matsukuma, K, McNamara, M, Merkow, RP, Miller, AM, Mukherjee, S, Mulcahy, MF, Perry, KA, Pimiento, JM, Reddi, DM, Reznik, S, Roses, RE, Strong, VE, Su, S, Uboha, N, Wainberg, ZA, Willett, CG, Woo, Y, Yoon, HH, McMillian, NR & Stein, ME 2025, 'Gastric Cancer, Version 2.2025', JNCCN Journal of the National Comprehensive Cancer Network, vol. 23, no. 5, pp. 169-191. https://doi.org/10.6004/jnccn.2025.0022

TY - JOUR

T1 - Gastric Cancer, Version 2.2025

AU - Ajani, Jaffer A.

AU - D’Amico, Thomas A.

AU - Bentrem, David J.

AU - Corvera, Carlos U.

AU - Das, Prajnan

AU - Enzinger, Peter C.

AU - Enzler, Thomas

AU - Gerdes, Hans

AU - Gibson, Michael K.

AU - Grierson, Patrick

AU - Gupta, Garima

AU - Hofstetter, Wayne L.

AU - Ilson, David H.

AU - Jalal, Shadia

AU - Kim, Sunnie

AU - Kleinberg, Lawrence R.

AU - Klempner, Samuel

AU - Lacy, Jill

AU - Lee, Byrne

AU - Licciardi, Frank

AU - Lloyd, Shane

AU - Ly, Quan P.

AU - Matsukuma, Karen

AU - McNamara, Michael

AU - Merkow, Ryan P.

AU - Miller, Aaron M.

AU - Mukherjee, Sarbajit

AU - Mulcahy, Mary F.

AU - Perry, Kyle A.

AU - Pimiento, Jose M.

AU - Reddi, Deepti M.

AU - Reznik, Scott

AU - Roses, Robert E.

AU - Strong, Vivian E.

AU - Su, Stacey

AU - Uboha, Nataliya

AU - Wainberg, Zev A.

AU - Willett, Christopher G.

AU - Woo, Yanghee

AU - Yoon, Harry H.

AU - McMillian, Nicole R.

AU - Stein, Mary Elizabeth

PY - 2025/5

Y1 - 2025/5

N2 - Gastric cancer is the fifth leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improve survival, and enhance the quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing has had a significant impact on clinical practice and patient care. Targeted therapies have demonstrated encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. This selection from the NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer highlights recommendations for biomarker testing and discusses updates for the treatment of advanced disease, including peritoneal carcinoma as only disease and unresectable locally advanced, recurrent, or metastatic disease.

AB - Gastric cancer is the fifth leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improve survival, and enhance the quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing has had a significant impact on clinical practice and patient care. Targeted therapies have demonstrated encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. This selection from the NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer highlights recommendations for biomarker testing and discusses updates for the treatment of advanced disease, including peritoneal carcinoma as only disease and unresectable locally advanced, recurrent, or metastatic disease.

UR - https://www.scopus.com/pages/publications/105004862556

U2 - 10.6004/jnccn.2025.0022

DO - 10.6004/jnccn.2025.0022

M3 - Article

C2 - 40341199

AN - SCOPUS:105004862556

SN - 1540-1405

VL - 23

SP - 169

EP - 191

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 5

ER -

Gastric Cancer, Version 2.2025

Abstract

Access to Document

Other files and links

Fingerprint

Cite this